Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Кафедра психиатрии, психотерапии и психосоматической патологии факультета повышения квалификации медицинских работников РУДН
Список исп. литературыСкрыть список 1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC. American Psychiatric Association Press 1994. 2. Bajt M, Gabrijelčič Blenkuš M, Jeriček Klanšček H et al. Duševno zdravje v Sloveniji. Ljubljana: Inštitut za varovanje zdravja Republike Slovenije 2009. 3. Burke WJ, Kratochvil ChJ. Stereoisomers in psychiatry. The case of escitalopram. Primary care companion. J Clin Psychiat 2002; 4: 20–4. 4. Cross-national comparisons of the prevalences and correlates of mental disorders. Bull WHO. 2000; 4 (78): 413–26. 5. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC. American Psychiatric Association 1994. 6. Francois C, Toumi M, Aakhus MA, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Eur J Health Econom 2003; 4: 12–9. 7. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 2002; 7: 40–4. 8. Hedges DW, Brown BL, Shwalb DA et al. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trial. J Clin Psychiat 2003; 64 (11): 1322–7. 9. Internationale Klassifikation psychischer Storungen: ICD 10. Bern, Gottingen, Toronto. Verlag Hans Huber 1991. 10. Plesničar KB. Epidemiologija, etiologija, klinična slika in diagnostika depresije. Farm Vest 2006; 57 (4): 241–4. 11. Montgomery SA, Lader M, Burger V et al. Escitalopram and paroxetine in fixed doses for the treatment of social anxiety disorder (SAD). Nord J Psychiat 2003; 57: 103. 12. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiol 2004; 50: 5764. 13. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 23: Depression. The treatment and management of depression in adults. London: National Institute for Health and Clinical Excellence 2009. http://www.nice.org.uk/nicemedia/live/12329/ 45888/45888.pdf 14. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiat 2001; 50: 345–50. 15. Wade A, Lemming OM, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95–102. 16. World Health Organization. Investing in mental health. Geneva: World Health Organization 2003. http://www.who.int/mental_health/en/investing_in_mnh_final.pdf